{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:03:00Z","timestamp":1791068580578,"version":"4.1.0"},"reference-count":133,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000914","name":"EADO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000914","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007308","name":"NeraCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007308","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"DOI":"10.13039\/501100008271","name":"Leo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012513","name":"Meda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012513","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"name":"PellePharm"},{"DOI":"10.13039\/501100008271","name":"Leo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ceries"},{"name":"Almirall"},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"Merck Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi-Aventis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"MSD\/Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Philogen"},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Biontech"},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014554","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014554","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005463","name":"Leo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005463","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004342","name":"Wyeth","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"Netherlands Organization for Health Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"name":"ISDIN"},{"DOI":"10.13039\/501100008271","name":"Leo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006365","name":"Cantabria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GSK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Immunocore"},{"DOI":"10.13039\/100002491","name":"BMS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007033","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005185","name":"Millennium","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011022","name":"Vertex","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TC Biopharm"},{"name":"BioLineRx"},{"name":"Replimune"},{"DOI":"10.13039\/100009104","name":"Modena and Reggio Emilia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"DOI":"10.13039\/501100008271","name":"Leo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Almirall"},{"DOI":"10.13039\/100005614","name":"Biogen Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"Leo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004755","name":"Merck Serono","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche-Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009754","name":"Galderma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Almirall"},{"name":"Leo Pharma"},{"name":"Mylan"},{"name":"Difa Cooper"},{"name":"Cieffe Labs"},{"DOI":"10.13039\/100007013","name":"La Roche Posay","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013226","name":"Pierre Fabre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.ejca.2020.01.008","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T08:32:18Z","timestamp":1582705938000},"page":"83-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":277,"special_numbering":"C","title":["European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment"],"prefix":"10.1016","volume":"128","author":[{"given":"Alexander J.","family":"Stratigos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Dessinioti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celeste","family":"Lebbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bastholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Dreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Concetta Fargnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana M.","family":"Forsea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecille","family":"Frenard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Harwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hauschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hoeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidija","family":"Kandolf-Sekulovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole W.J.","family":"Kelleners-Smeets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Malvehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"del Marmol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Moreno-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Pellecani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ketty","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke H.J.","family":"van den Beuken-van Everdingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Zalaudek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.M.","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Grob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.01.008_bib1","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. In: Group OLoEW, editor. The Oxford Levels of Evidence 2: Oxford Center for Evifdence-Based Medicine. https:\/\/www.cebm.net\/index.aspx?o=5653. [Accessed23 April 2019]."},{"key":"10.1016\/j.ejca.2020.01.008_bib2","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/jso.23155","article-title":"The incidence of metastasis from cutaneous squamous cell carcinoma and the impact of its risk factors","volume":"106","author":"Brougham","year":"2012","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/1754-9485.12842","article-title":"Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma","volume":"63","author":"Joseph","year":"2019","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib4","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2018.01.075","article-title":"Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG","volume":"96","author":"Hillen","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib5","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S1470-2045(08)70178-5","article-title":"Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study","volume":"9","author":"Brantsch","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib6","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/jid.2012.403","article-title":"Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma","volume":"133","author":"Chren","year":"2013","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2005.02.059","article-title":"Cutaneous squamous cell carcinoma treated with Mohs micrographic surgery in Australia I. Experience over 10 years","volume":"53","author":"Leibovitch","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib8","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1524-4725.2010.01576.x","article-title":"Mohs surgery is effective for high-risk cutaneous squamous cell carcinoma","volume":"36","author":"Pugliano-Mauro","year":"2010","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2018.09.015","article-title":"Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone","volume":"80","author":"Marrazzo","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/bjd.17188","article-title":"Recurrence rates of cutaneous squamous cell carcinoma of the head and neck after Mohs micrographic surgery vs. standard excision: a retrospective cohort study","volume":"181","author":"van Lee","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib11","doi-asserted-by":"crossref","first-page":"f6153","DOI":"10.1136\/bmj.f6153","article-title":"Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies","volume":"347","author":"Lansbury","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2020.01.008_bib12","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1468-3083.2007.02187.x","article-title":"A confusing world: what to call histology of three-dimensional tumour margins?","volume":"21","author":"Moehrle","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2020.01.008_bib13","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ddg.12665","article-title":"S1 guideline: microscopically controlled surgery (MCS)","volume":"13","author":"Loser","year":"2015","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2020.01.008_bib14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(92)70178-I","article-title":"Surgical margins for excision of primary cutaneous squamous cell carcinoma","volume":"27","author":"Brodland","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib15","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1524-4725.2009.01095.x","article-title":"Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes","volume":"35","author":"Jambusaria-Pahlajani","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib16","series-title":"NCCN Clinical Practice Guidelines in Oncology. Squamous cell Skin Cancer","author":"National Comprehensive Cancer Network","year":"2018"},{"key":"10.1016\/j.ejca.2020.01.008_bib17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/jso.24870","article-title":"Effective excision of cutaneous squamous cell carcinoma of the face using analysis of intra-operative frozen sections from the whole specimen","volume":"117","author":"Hutting","year":"2018","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1111\/ced.12743","article-title":"False-negative rate of intraoperative frozen section margin analysis for complex head and neck nonmelanoma skin cancer excisions","volume":"40","author":"Moncrieff","year":"2015","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/PAP.0000000000000157","article-title":"Cutaneous squamous cell carcinoma: review of the eighth edition of the American Joint Committee on Cancer Staging Guidelines, Prognostic Factors, and Histopathologic Variants","volume":"24","author":"Motaparthi","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ejca.2020.01.008_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.PRS.0000067479.77859.31","article-title":"Excision margins for nonmelanotic skin cancer","volume":"112","author":"Thomas","year":"2003","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000444051","article-title":"Squamocellular carcinoma of the skin: clinicopathological features predicting the involvement of the surgical margins and review of the literature","volume":"232","author":"Ribero","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2020.01.008_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0007-1226(03)00028-6","article-title":"British Association of D, British Association of Plastic S. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma","volume":"56","author":"Motley","year":"2003","journal-title":"Br J Plast Surg"},{"issue":"Suppl 5","key":"10.1016\/j.ejca.2020.01.008_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2011.04296.x","article-title":"Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma and precursor lesions","volume":"25","author":"Bonerandi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2020.01.008_bib24","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/1203475415582318","article-title":"Non-melanoma Skin Cancer in Canada Chapter 5: management of Squamous Cell Carcinoma","volume":"19","author":"Sapijaszko","year":"2015","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib25","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.ejca.2015.06.110","article-title":"Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline","volume":"51","author":"Stratigos","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib26","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jaad.2017.10.007","article-title":"Guidelines of care for the management of cutaneous squamous cell carcinoma","volume":"78","author":"Work","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib27","series-title":"Clinical Practice Guidelines in Oncology. Cutaneous Melanoma","author":"National Comprehensive Cancer Network (NCCN)","year":"2019"},{"issue":"Suppl 3","key":"10.1016\/j.ejca.2020.01.008_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/ddg.12015_7","article-title":"Brief S2k guidelines \u2013 cutaneous squamous cell carcinoma","volume":"11","author":"Breuninger","year":"2013","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.ejca.2020.01.008_bib29","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1017\/S0022215116000554","article-title":"Non-melanoma skin cancer: United Kingdom National Multidisciplinary Guidelines","volume":"130","author":"Newlands","year":"2016","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ejca.2020.01.008_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0190-9622(92)70144-5","article-title":"Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection","volume":"26","author":"Rowe","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib31","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1097\/01.MLG.0000158349.64337.ED","article-title":"Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice","volume":"115","author":"Veness","year":"2005","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2020.01.008_bib32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.bjoms.2014.01.015","article-title":"Management of regional metastatic disease in head and neck cutaneous malignancy. 1. Cutaneous squamous cell carcinoma","volume":"52","author":"Gurney","year":"2014","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MOO.0b013e328343e811","article-title":"Management of the neck in metastatic cutaneous squamous cell carcinoma of the head and neck","volume":"19","author":"D\u2019Souza","year":"2011","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hed.10063","article-title":"Significance of clinical stage, extent of surgery, and pathologic findings in metastatic cutaneous squamous carcinoma of the parotid gland","volume":"24","author":"O\u2019Brien","year":"2002","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib35","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/hed.20417","article-title":"Patterns of lymph node spread of cutaneous squamous cell carcinoma of the head and neck","volume":"28","author":"Vauterin","year":"2006","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib36","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hed.21574","article-title":"Outcome of patients treated surgically for lymph node metastases from cutaneous squamous cell carcinoma of the head and neck","volume":"33","author":"Givi","year":"2011","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib37","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/hed.21332","article-title":"Predicting the pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck based on location of the primary","volume":"32","author":"Ebrahimi","year":"2010","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/ejso.2002.1330","article-title":"Treatment results of regional metastasis from cutaneous head and neck squamous cell carcinoma","volume":"29","author":"Jol","year":"2003","journal-title":"Eur J Surg Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ejca.2020.01.008_bib39","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1017\/S0022215112002101","article-title":"In patients with metastatic cutaneous head and neck squamous cell carcinoma to cervical lymph nodes, the extent of neck dissection does not influence outcome","volume":"127","author":"Wang","year":"2013","journal-title":"J Laryngol Otol"},{"key":"10.1016\/j.ejca.2020.01.008_bib40","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/hed.23843","article-title":"Outcomes of nodal metastatic cutaneous squamous cell carcinoma of the head and neck treated in a regional center","volume":"37","author":"Schmidt","year":"2015","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib41","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/hed.20048","article-title":"Cutaneous metastatic squamous cell carcinoma to the parotid gland: analysis and outcome","volume":"26","author":"Audet","year":"2004","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib42","doi-asserted-by":"crossref","first-page":"e10782","DOI":"10.1097\/MD.0000000000010782","article-title":"Comparison between wait-and-see policy and elective neck dissection in clinically N0 cutaneous squamous cell carcinoma of head and neck","volume":"97","author":"Xiao","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ejca.2020.01.008_bib43","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1177\/0194599817691923","article-title":"Elective neck dissection for head and neck cutaneous squamous cell carcinoma with skull base invasion","volume":"156","author":"Cannon","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib44","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/hed.25561","article-title":"Elective neck dissection in metastatic cutaneous squamous cell carcinoma to the parotid gland: a systematic review and meta-analysis","volume":"41","author":"Rotman","year":"2019","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1684\/ejd.2015.2570","article-title":"European Dermatology Forum Guidelines on topical photodynamic therapy","volume":"25","author":"Morton","year":"2015","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib46","doi-asserted-by":"crossref","first-page":"9489163","DOI":"10.1155\/2018\/9489163","article-title":"A review of the literature of surgical and nonsurgical treatments of invasive squamous cells carcinoma","volume":"2018","author":"Potenza","year":"2018","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.ejca.2020.01.008_bib47","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2017.04.1108","article-title":"Efficacy of curettage alone for invasive cutaneous squamous cell carcinoma: a retrospective cohort study","volume":"77","author":"Yakish","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0190-9622(80)80007-7","article-title":"Successful treatment of keratoacanthoma with intralesional fluorouracil","volume":"2","author":"Goette","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib49","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaad.2006.12.017","article-title":"Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature","volume":"56","author":"Annest","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib50","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1111\/bjd.15225","article-title":"An 18-year retrospective study on the outcomes of keratoacanthomas with different treatment modalities at a single academic centre","volume":"177","author":"Tran","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1684\/ejd.2013.2106","article-title":"Post radiation skin tumors: basal cell carcinomas, squamous cell carcinomas and angiosarcomas. A review of this late effect of radiotherapy","volume":"23","author":"Cuperus","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.fsc.2018.08.005","article-title":"Radiotherapy for skin cancers of the face, head, and neck","volume":"27","author":"Mierzwa","year":"2019","journal-title":"Facial Plast Surg Clin North Am"},{"issue":"4","key":"10.1016\/j.ejca.2020.01.008_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ajd.13025","article-title":"The role of radiotherapy in the management of non-melanoma skin cancer","volume":"60","author":"Garbutcheon-Singh","year":"2019","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib54","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1111\/bjd.15728","article-title":"Outcomes of radiation therapy for advanced T3\/T4 nonmelanoma cutaneous squamous cell and basal cell carcinoma","volume":"178","author":"Kim","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib55","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/coa.12707","article-title":"Local control of 151 head and neck cutaneous squamous cell carcinoma after radiotherapy: a retrospective study on efficacy and prognostic factors","volume":"42","author":"Terra","year":"2017","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.ejca.2020.01.008_bib56","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/jamaoto.2018.3650","article-title":"Association of adjuvant radiation therapy with survival in patients with advanced cutaneous squamous cell carcinoma of the head and neck","volume":"145","author":"Harris","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib57","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/DSS.0000000000001827","article-title":"Outcomes of adjuvant radiotherapy following negative surgical margins for cutaneous squamous cell carcinoma","volume":"45","author":"Miller","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib58","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjd.17244","article-title":"Local recurrence and quality of life after adjuvant radiation therapy in high-risk squamous cell carcinoma","volume":"180","author":"Yan","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib59","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0190-9622(94)70073-7","article-title":"Adjuvant radiotherapy after excision of cutaneous squamous cell carcinoma","volume":"30","author":"Geohas","year":"1994","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib60","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1002\/cncr.21898","article-title":"High-risk cutaneous squamous cell carcinoma of the head and neck: results from 266 treated patients with metastatic lymph node disease","volume":"106","author":"Veness","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib61","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/cncr.22509","article-title":"What is the role of adjuvant radiotherapy in the treatment of cutaneous squamous cell carcinoma with perineural invasion?","volume":"109","author":"Han","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib62","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1200\/JCO.2017.77.0941","article-title":"Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial","volume":"36","author":"Porceddu","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib63","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoto.2018.4515","article-title":"Outcomes of cutaneous squamous cell carcinoma in the head and neck region with regional lymph node metastasis: a systematic review and meta-analysis","volume":"145","author":"Sahovaler","year":"2019","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib64","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/hed.21965","article-title":"Predictors of outcome in patients with metastatic cutaneous head and neck squamous cell carcinoma involving cervical lymph nodes: improved survival with the addition of adjuvant radiotherapy","volume":"34","author":"Wang","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2020.01.008_bib65","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib66","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ijrobp.2012.09.030","article-title":"Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma","volume":"85","author":"Heath","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejca.2020.01.008_bib67","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2006.05.9873","article-title":"Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma","volume":"25","author":"Brewster","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib68","first-page":"e1784","article-title":"Role of concurrent systemic therapy with adjuvant radiation therapy for locally advanced cutaneous head and neck squamous cell carcinoma","volume":"9","author":"Goyal","year":"2017","journal-title":"Cureus"},{"key":"10.1016\/j.ejca.2020.01.008_bib69","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.oraloncology.2018.01.015","article-title":"Combination of post-operative radiotherapy and cetuximab for high-risk cutaneous squamous cell cancer of the head and neck: a propensity score analysis","volume":"78","author":"Palmer","year":"2018","journal-title":"Oral Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib70","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/jdv.13266","article-title":"Neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a comparative cohort study","volume":"30","author":"Salido-Vallejo","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2020.01.008_bib71","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/bjd.13741","article-title":"Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas","volume":"173","author":"Reigneau","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib72","doi-asserted-by":"crossref","first-page":"e000003","DOI":"10.1136\/esmoopen-2015-000003","article-title":"A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis","volume":"1","author":"Jenni","year":"2016","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2020.01.008_bib73","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","article-title":"A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck","volume":"18","author":"Lewis","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.01.008_bib74","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1097\/DSS.0000000000000864","article-title":"In-transit metastasis from squamous cell carcinoma","volume":"42","author":"Ma","year":"2016","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib75","first-page":"651","article-title":"In-transit metastasis from primary cutaneous squamous cell carcinoma in organ transplant recipients and nonimmunosuppressed patients: clinical characteristics, management, and outcome in a series of 21 patients","volume":"30","author":"Carucci","year":"2004","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib76","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jso.23481","article-title":"Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patients treated with palliative intent","volume":"109","author":"Solari","year":"2014","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib77","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41416-018-0149-z","article-title":"Isolated limb perfusion for unresectable extremity cutaneous squamous cell carcinoma; an effective limb saving strategy","volume":"119","author":"Huis In \u2018t Veld","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib78","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib79","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib80","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejca.2020.01.008_bib81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib82","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/jid.2011.9","article-title":"Tumor-associated macrophages in the cutaneous SCC microenvironment are heterogeneously activated","volume":"131","author":"Pettersen","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib83","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/jamadermatol.2013.1609","article-title":"CD200 upregulation in vascular endothelium surrounding cutaneous squamous cell carcinoma","volume":"149","author":"Belkin","year":"2013","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib84","unstructured":"European Medicines Agency. Libtayo. Summary of product characteristics. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/libtayo-epar-product-information_en.pdf Access date: 17 July 2019."},{"key":"10.1016\/j.ejca.2020.01.008_bib85","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-17-0539","article-title":"Immunotherapy of Lymphoma and Myeloma: facts and Hopes","volume":"24","author":"Pianko","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.01.008_bib86","article-title":"Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review","author":"Fisher","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib87","first-page":"1205","article-title":"Immunohistochemical analysis of EGFR and HER-2 in patients with metastatic squamous cell carcinoma of the skin","volume":"25","author":"Maubec","year":"2005","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2020.01.008_bib88","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/jid.2009.312","article-title":"Somatic mutation of epidermal growth factor receptor in a small subset of cutaneous squamous cell carcinoma","volume":"130","author":"Ridd","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib89","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/annonc\/mdu368","article-title":"Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma","volume":"25","author":"Foote","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamadermatol.2015.4134","article-title":"Complete remission of squamous cell carcinoma after treatment with panitumumab in a patient with cetuximab-induced anaphylaxis","volume":"152","author":"Marti","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2017.07.048","article-title":"Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial","volume":"77","author":"William","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib92","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1002\/cncr.31346","article-title":"Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial","volume":"124","author":"Gold","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib93","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/DSS.0000000000000799","article-title":"Cisplatin and cetuximab treatment for metastatic cutaneous squamous cell carcinoma: a systematic review","volume":"43","author":"Trodello","year":"2017","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib94","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamadermatol.2017.0270","article-title":"Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab","volume":"153","author":"Picard","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib95","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000362384","article-title":"Cetuximab in metastatic squamous cell cancer of the skin: a Swiss case series","volume":"229","author":"Conen","year":"2014","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2020.01.008_bib96","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib97","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1159\/000461578","article-title":"Efficacy and tolerance of cetuximab alone or combined with chemotherapy in locally advanced or metastatic cutaneous squamous cell carcinoma: an open study of 14 patients","volume":"232","author":"Dereure","year":"2016","journal-title":"Dermatology"},{"key":"10.1016\/j.ejca.2020.01.008_bib98","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.clon.2011.07.007","article-title":"Efficacy of cetuximab for unresectable or advanced cutaneous squamous cell carcinoma\u2013a report of eight cases","volume":"23","author":"Giacchero","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.ejca.2020.01.008_bib99","doi-asserted-by":"crossref","first-page":"284582","DOI":"10.1155\/2014\/284582","article-title":"Locally advanced and unresectable cutaneous squamous cell carcinoma: outcomes of concurrent cetuximab and radiotherapy","volume":"2014","author":"Samstein","year":"2014","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/DSS.0000000000001755","article-title":"Cetuximab as a component of multimodality treatment of high-risk cutaneous squamous cell carcinoma: a retrospective analysis from a single tertiary academic medical center","volume":"45","author":"Trodello","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/DSS.0000000000001583","article-title":"Response of cutaneous squamous cell carcinoma to treatment with cetuximab","volume":"45","author":"Berliner","year":"2019","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.ejca.2020.01.008_bib102","first-page":"1935","article-title":"Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck","volume":"59","author":"Huang","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2020.01.008_bib103","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/09546634.2012.751481","article-title":"Efficacy of cetuximab in the treatment of squamous cell carcinoma","volume":"25","author":"Preneau","year":"2014","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ejca.2020.01.008_bib104","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/CCO.0000000000000359","article-title":"Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?","volume":"29","author":"Ribero","year":"2017","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib105","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.1990.8.2.342","article-title":"Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy","volume":"8","author":"Guthrie","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib106","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s00432-004-0656-6","article-title":"Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin","volume":"131","author":"Wollina","year":"2005","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib107","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00000421-200004000-00015","article-title":"Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged","volume":"23","author":"Cartei","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib108","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1200\/JCO.2002.20.2.364","article-title":"Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer","volume":"20","author":"Shin","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib109","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1684\/ejd.2012.1845","article-title":"Complete response of metastatic cutaneous squamous cell carcinoma to cetuximab plus paclitaxel","volume":"22","author":"Mecca","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib110","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/COC.0000000000000088","article-title":"Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the roswell park experience and a review of the literature","volume":"39","author":"Jarkowski","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib111","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1080\/0284186X.2018.1454602","article-title":"Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases","volume":"57","author":"Gehl","year":"2018","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib112","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1529-8019.2010.01370.x","article-title":"Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach","volume":"23","author":"Testori","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejca.2020.01.008_bib113","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12967-017-1186-8","article-title":"Electrochemotherapy efficacy evaluation for treatment of locally advanced stage III cutaneous squamous cell carcinoma: a 22-cases retrospective analysis","volume":"15","author":"Di Monta","year":"2017","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib114","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/jdv.14708","article-title":"Electrochemotherapy of unresectable cutaneous tumours with reduced dosages of intravenous bleomycin: analysis of 57 patients from the International Network for Sharing Practices of Electrochemotherapy registry","volume":"32","author":"Rotunno","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.ejca.2020.01.008_bib115","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1684\/ejd.2018.3291","article-title":"Application of electrochemotherapy in the management of primary and metastatic cutaneous malignant tumours: a systematic review and meta-analysis","volume":"28","author":"Seyed Jafari","year":"2018","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib116","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2016.05.001","article-title":"European Research on Electrochemotherapy in Head and Neck Cancer (EURECA) project: results of the treatment of skin cancer","volume":"63","author":"Bertino","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib117","unstructured":"www.clinicaltrials.gov Accessed on 5 May, 2019."},{"key":"10.1016\/j.ejca.2020.01.008_bib118","unstructured":"www.ClinicalTrials.gov. Study of adjuvant cemipllimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma. Accessed on: 20 July 2019."},{"key":"10.1016\/j.ejca.2020.01.008_bib119","doi-asserted-by":"crossref","first-page":"165","DOI":"10.21037\/apm.2016.11.10","article-title":"Palliative radiotherapy for skin malignancies","volume":"6","author":"Vuong","year":"2017","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib120","unstructured":"Organization WH. WHO Definition of Palliative Care. https:\/\/www.who.int\/cancer\/palliative\/definition\/en\/. Last accessed on 15 January 2019."},{"key":"10.1016\/j.ejca.2020.01.008_bib121","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1053\/ejso.1999.0931","article-title":"Educational tips in the treatment of malignant ulcerating tumours of the skin","volume":"26","author":"van Leeuwen","year":"2000","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2020.01.008_bib122","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1097\/01.ASW.0000383206.32244.e2","article-title":"Local wound care for malignant and palliative wounds","volume":"23","author":"Woo","year":"2010","journal-title":"Adv Skin Wound Care"},{"key":"10.1016\/j.ejca.2020.01.008_bib123","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/SPC.0000000000000261","article-title":"Pain prevalence in cancer patients: status quo or opportunities for improvement?","volume":"11","author":"Haumann","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"key":"10.1016\/j.ejca.2020.01.008_bib124","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2147\/JPR.S97759","article-title":"Effectiveness of the World Health Organization cancer pain relief guidelines: an integrative review","volume":"9","author":"Carlson","year":"2016","journal-title":"J Pain Res"},{"key":"10.1016\/j.ejca.2020.01.008_bib125","doi-asserted-by":"crossref","first-page":"146","DOI":"10.5114\/aoms.2018.72566","article-title":"Topical morphine for treatment of cancer-related painful mucosal and cutaneous lesions: a double-blind, placebo-controlled cross-over clinical trial","volume":"15","author":"Cialkowska-Rysz","year":"2019","journal-title":"Arch Med Sci"},{"key":"10.1016\/j.ejca.2020.01.008_bib126","first-page":"11","article-title":"Improved morphine-loaded hydrogels for wound-related pain relief","author":"Mateus","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejca.2020.01.008_bib127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/0269216318812633","article-title":"Integrated outpatient palliative care for patients with advanced cancer: a systematic review and meta-analysis","volume":"33","author":"Fulton","year":"2019","journal-title":"Palliat Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib128","doi-asserted-by":"crossref","first-page":"e1001433","DOI":"10.1371\/journal.pmed.1001433","article-title":"Risk of a second primary cancer after non-melanoma skin cancer in white men and women: a prospective cohort study","volume":"10","author":"Song","year":"2013","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2020.01.008_bib129","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamadermatol.2014.3307","article-title":"Timing of subsequent new tumors in patients who present with basal cell carcinoma or cutaneous squamous cell carcinoma","volume":"151","author":"Wehner","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib130","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.ejca.2013.03.010","article-title":"Risk of subsequent cutaneous malignancy in patients with prior keratinocyte carcinoma: a systematic review and meta-analysis","volume":"49","author":"Flohil","year":"2013","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2020.01.008_bib131","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/bjd.15931","article-title":"Epidemiology of keratinocyte carcinomas after organ transplantation","volume":"177","author":"Madeleine","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ejca.2020.01.008_bib132","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-6143.2012.04292.x","article-title":"A surveillance model for skin cancer in organ transplant recipients: a 22-year prospective study in an ethnically diverse population","volume":"13","author":"Harwood","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ejca.2020.01.008_bib133","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/bjd.16900","article-title":"Needs and preferences of patients regarding basal cell carcinoma and cutaneous squamous cell carcinoma care: a qualitative focus group study","volume":"180","author":"van Egmond","year":"2019","journal-title":"Br J Dermatol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920300198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:27:15Z","timestamp":1760732835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920300198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":133,"alternative-id":["S0959804920300198"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.008","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}